📊 AZTR Key Takeaways
Investment Thesis
Azitra is a pre-revenue pharmaceutical company with severe cash burn and deteriorating financial position. The company is consuming $11.2M in annual operating cash flow with only $2.1M in cash reserves, creating an acute liquidity crisis within months. Negative profitability, zero revenue generation, and massive operating losses indicate the company is not executing on its business model.
AZTR Strengths
- Current ratio of 2.83x provides short-term liquidity cushion
- Minimal debt burden with 0.00x debt-to-equity ratio reduces financial leverage risk
- Recent insider activity suggests management engagement with business
AZTR Risks
- Zero revenue with -$11.0M net loss indicates complete commercial failure or pre-commercial stage misrepresentation
- Operating cash burn of -$11.2M annually against $2.1M cash reserves means runway exhausted within 2-3 months
- Negative ROE of -288.2% and ROA of -218.0% demonstrate severe value destruction
- Stockholders' equity of $3.8M being depleted rapidly, risking equity dilution or insolvency
- No visible path to profitability with pharmaceutical development cycle requirements
Key Metrics to Watch
- Quarterly cash burn rate and remaining cash runway
- Revenue recognition milestone or clinical trial progression
- Equity dilution and financing activities
- Operating cash flow trajectory and burn rate stabilization
AZTR Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 2.83x current ratio provides a solid financial cushion.
AZTR Profitability Ratios
AZTR vs Healthcare Sector
How Azitra, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
AZTR Balance Sheet & Liquidity
AZTR 5-Year Financial Trend
5-Year Trend Summary: Azitra, Inc.'s revenue has declined by 99% over the 5-year period, indicating business contraction. The most recent EPS of $-15.70 indicates the company is currently unprofitable.
AZTR Growth Metrics (YoY)
AZTR Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$1.0M | $-0.67 |
| Q2 2025 | N/A | -$2.6M | $-0.18 |
| Q3 2024 | N/A | -$1.0M | $-0.17 |
| Q2 2024 | $7.5K | -$2.5M | $-2.74 |
| Q1 2024 | N/A | -$2.5M | $-0.15 |
| Q3 2023 | $48.5K | -$1.9M | $-0.16 |
| Q2 2023 | $85.0K | -$1.9M | $-2.36 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
AZTR Capital Allocation
AZTR SEC Filings
Access official SEC EDGAR filings for Azitra, Inc. (CIK: 0001701478)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AZTR
What is the AI rating for AZTR?
Azitra, Inc. (AZTR) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are AZTR's key strengths?
Current ratio of 2.83x provides short-term liquidity cushion. Minimal debt burden with 0.00x debt-to-equity ratio reduces financial leverage risk.
What are the risks of investing in AZTR?
Zero revenue with -$11.0M net loss indicates complete commercial failure or pre-commercial stage misrepresentation. Operating cash burn of -$11.2M annually against $2.1M cash reserves means runway exhausted within 2-3 months.
What is AZTR's revenue and growth?
Azitra, Inc. reported revenue of $0.0.
Does AZTR pay dividends?
Azitra, Inc. does not currently pay dividends.
Where can I find AZTR SEC filings?
Official SEC filings for Azitra, Inc. (CIK: 0001701478) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AZTR's EPS?
Azitra, Inc. has a diluted EPS of $-2.25.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.